Third Arc Bio has raised a $52 million Series A extension, adding to its previously announced $165 million round, to accelerate development of its oncology and immunology & inflammation (I&I) portfolio. The financing was led by new investor Andreessen Horowitz (a16z), alongside founding investor Omega Funds, with participation from a broad syndicate of life sciences and institutional investors. a16z General Partner Jorge Conde will join the company’s Board of Directors, further strengthening governance as Third Arc advances its pipeline. The proceeds will support rapid expansion of the company’s I&I programs and the progression of additional oncology assets into clinical development.
Also Read: Embold Health Launches Embold Edge Quality-Driven Health Plan
“Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease,” said Jorge Conde, General Partner at a16z. The company’s lead program, ARC101, is already in Phase 1 trials for advanced solid tumors, while its ARCTag platform aims to localize immune activity directly at disease sites. “This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies,” said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio.